• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    $ICU
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER HERE

    Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams.

    Schedule 1x1 meetings here

    "We are delighted to highlight today's innovators from the Life Science sector," said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. "Our Virtual Investor Conferences continue to provide an efficient platform and unique opportunity for these companies to engage to a broader investor base and communicate their strategies."

    March 11th

    Eastern

    Time (ET)
    PresentationTicker(s)
    12:00 PMSeaStar Medical Holding Corporation(NASDAQ:ICU)
    12:30 PMNasus Pharma Ltd.(NYSE:NSRX)
    1:00 PMTonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)
    1:30 PMJupiter Neurosciences, Inc.(NASDAQ:JUNS)



    March 12th

    Eastern

    Time (ET)
    PresentationTicker(s)
    09:30 AMBora Pharmaceuticals Co., Ltd.(OTCQX:BORAY, TWSE: 6472))
    10:00 AMProstatype Genomics AB(OTCQB:PGABF, NASDAQ Stockholm: PROGEN)) 
    10:30 AMMetaVia Inc.(NASDAQ:MTVA)
    11:00 AMPhio Pharmaceuticals Corp.(NASDAQ:PHIO)
    11:30 AMAvicanna Inc.(OTCQX:AVCNF, TSX:AVCN)
    12:00 PMEMVision Medical Devices Ltd.(OTC:EMVDF, ASX: EMV))
    1:00 PMAethlon Medical, Inc.(NASDAQ:AEMD)
    1:30 PMDyadic International, Inc.(NASDAQ:DYAI)
    2:00 PMJaguar Health, Inc.(NASDAQ:JAGX)
    2:30 PMBeyond Air, Inc.(NASDAQ:XAIR)
    3:00 PMCadrenal Therapeutics, Inc.(NASDAQ:CVKD)
    3:30 PMAmplia Therapeutics Ltd.(OTCQB:INNMF, ASX: ATX))



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    johnv@otcmarkets.com



    Primary Logo

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $CVKD
    $DYAI
    $ICU

    CompanyDatePrice TargetRatingAnalyst
    Tonix Pharmaceuticals Holding Corp.
    $TNXP
    5/4/2026$22.00Buy
    TD Cowen
    Dyadic International Inc.
    $DYAI
    10/23/2025$3.00Buy
    H.C. Wainwright
    Dyadic International Inc.
    $DYAI
    9/8/2025Buy
    Craig Hallum
    MetaVia Inc.
    $MTVA
    9/4/2025$12.00Buy
    H.C. Wainwright
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    MetaVia Inc.
    $MTVA
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Hayward Marshall A.

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    6/4/26 9:00:06 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Elmasri Saleem

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    6/4/26 9:01:20 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and COO Silva Alison D.

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    6/4/26 9:00:07 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

    CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present an update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET. After the presentation, MetaVia's management will open the floor for questions. Attendees may submit questions in advance to questions@emerginggrowth.com, or ask questi

    6/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

    Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is a potential target for therapy and prevention of cancer Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support

    6/3/26 9:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026

    SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note t

    6/2/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Tonix Pharma with a new price target

    TD Cowen initiated coverage of Tonix Pharma with a rating of Buy and set a new price target of $22.00

    5/4/26 8:35:45 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Dyadic International with a new price target

    H.C. Wainwright resumed coverage of Dyadic International with a rating of Buy and set a new price target of $3.00

    10/23/25 7:06:50 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Dyadic International

    Craig Hallum initiated coverage of Dyadic International with a rating of Buy

    9/8/25 8:52:07 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    SEC Filings

    View All

    Aethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    6/4/26 9:00:39 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Aethlon Medical Inc.

    424B5 - AETHLON MEDICAL INC (0000882291) (Filer)

    6/4/26 9:00:38 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

    6/3/26 4:25:25 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:40:17 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Financials

    Live finance-specific insights

    View All

    Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026

    SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note t

    6/2/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

    Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industryCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership, while advancing scale-up and commercialization activities for additional recombinant products, including transferrinSigned an OEM distribution agreement with IBT Bioservices to commercialize Dy

    5/13/26 4:05:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

    PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting continued progress in its CAD-1005 program for HIT. The Company has now received the official minutes from its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), which provided guidance on key elements of the planned pivotal Phase 3 registration trial for CAD-1005, Cadrenal's investigational first-in-class 12-lipoxygenase (12-

    5/7/26 8:30:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Leadership Updates

    Live Leadership Updates

    View All

    Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board

    New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. JUPITER, FL, April 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the appointment of Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board. The two bring direct distribution relationships across compounding pharmacies and wellness channels, an addressable market th

    4/7/26 8:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

    GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th

    3/26/26 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions

    3/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care